Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax Combined With Azacitidine Plus Targeted Drugs in Newly Diagnosed Adult AML
NCT07548710Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Started May 2026; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07548710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548710.